Safety and efficacy of inebilizumab for the treatment of neuromyelitis optica spectrum disorder: end-of-study results from the open-label period of the N-MOmentum trial

Bruce Cree, Ho Jin Kim, Brian G. Weinshenker, Sean J. Pittock, Dean M. Wingerchuk, Kazuo Fujihara, Friedemann Paul, Gary Cutter, Romain Marignier, Ari Green, Orhan Aktaş, Hans‐Peter Hartung, Dewei She, William A. Rees, Michael Smith, Daniel Cimbora, Eliezer Katz, Jeffrey L. Bennett